Tissue Repair Ltd (ASX: TRP) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Tissue Repair Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$10.88 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
60.46 million
Earnings per share
-0.070
Dividend per share
N/A
Year To Date Return
-35.71%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Tissue Repair Ltd (ASX: TRP)
Latest News
Healthcare Shares
2 ASX biotech shares rocketing more than 40% on big news
IPOs
IPO flop: Tissue Repair (ASX:TRP) share price plunges 40% since listing
TRP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Tissue Repair Ltd
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.
TRP Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Jun 2025 | $0.18 | $0.00 | 0.00% | 11,484 | $0.18 | $0.18 | $0.18 |
| 05 Jun 2025 | $0.18 | $-0.01 | -5.41% | 20,258 | $0.17 | $0.18 | $0.17 |
| 04 Jun 2025 | $0.19 | $0.00 | 0.00% | 95,206 | $0.18 | $0.19 | $0.18 |
| 28 May 2025 | $0.19 | $0.00 | 0.00% | 87,612 | $0.19 | $0.19 | $0.18 |
| 26 May 2025 | $0.19 | $-0.01 | -5.26% | 48,094 | $0.19 | $0.19 | $0.19 |
| 23 May 2025 | $0.19 | $-0.01 | -5.13% | 130,119 | $0.19 | $0.19 | $0.17 |
| 20 May 2025 | $0.20 | $0.00 | 0.00% | 25,001 | $0.20 | $0.20 | $0.20 |
| 19 May 2025 | $0.20 | $0.01 | 5.26% | 18,515 | $0.20 | $0.20 | $0.20 |
| 16 May 2025 | $0.19 | $0.00 | 0.00% | 15,743 | $0.19 | $0.19 | $0.19 |
| 15 May 2025 | $0.19 | $-0.01 | -5.13% | 2,879 | $0.19 | $0.19 | $0.19 |
| 14 May 2025 | $0.20 | $0.00 | 0.00% | 157,570 | $0.19 | $0.20 | $0.19 |
| 13 May 2025 | $0.20 | $0.00 | 0.00% | 3,539 | $0.20 | $0.20 | $0.20 |
| 12 May 2025 | $0.20 | $0.00 | 0.00% | 34,649 | $0.20 | $0.20 | $0.20 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 12 Nov 2024 | Tony Charara | Issued | 750,000 | $191,250 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Tony Charara | Co-FounderExecutive Director | May 2012 |
Mr Charara is a co-founder of Tissue Repair. He has been involved in the Company's clinical development program, across its two-phase 2B trials, commercialization strategy and overall operations. Tony is an investment banker by background and has experience across early-stage venture assets and in advising technology companies at ANZ Investment Bank, Ord Minnett Securities and JPMorgan in their investment banking teams. Tony is also a co-founder of Mable Technologies, an online marketplace and health technology platform operating in the aged care and disability sectors.
|
| Mr Alistair Gregory McKeough | Non-Executive Director | Oct 2024 |
Mr McKeough has experience as a director of private and listed corporations in many sectors, including professional services, corporate services, regulatory technology, sports technology, charities, education and biotech. He was formerly Head of Professional Services at Automic Group, where he led the legal and company secretarial teams. Mr McKeough is currently a non-executive director of Recce Pharmaceuticals Ltd (ASX:RCE). Mr McKeough will serve as Chair of TRPs board.
|
| Mr Patryk Kania | Non-Executive Director | Oct 2024 |
Mr Kania is a medical device executive and brings over 20 years commercialisation and leadership experience in Medical Devices, Pharma, and Health Technologies, within sales and marketing management, and general management, working across the US, Europe and APAC. Mr Kanias commercial experience spans public organisations and early stage start-ups. Patryk is CEO and President USA, and Managing Director of Field Orthopaedics Ltd. He has previously held senior roles at Smith Nephew, Abbott, J&J Medical and Roche. Patryk also currently serves as non-executive director of EMVision Medical Devices Ltd (ASX:EMV).
|
| Ms Sushma Kejriwal | Company Secretary | Mar 2024 |
-
|
| Sushma Kejriwal | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Selene Holdings Ltd | 5,955,980 | 9.85% |
| Spark Capital Pty Limited | 4,822,260 | 7.98% |
| Creight Investments Pty Ltd <987 Trust A/C> | 3,031,720 | 5.01% |
| Welas Pty Ltd <Wales Family Trust A/C> | 2,317,580 | 3.83% |
| Mark Deacon Shaw | 2,035,160 | 3.37% |
| Hishenk Pty Ltd | 2,000,000 | 3.31% |
| Bannaby Investments Pty Limited | 1,690,580 | 2.80% |
| Moore Family Nominee Pty Limited | 1,217,400 | 2.01% |
| Gidley Baird Holdings Pty Ltd | 1,055,440 | 1.75% |
| Mr Guy Banducci & Mrs Lisa Maree Banducci <Kali Super Fund A/C> | 1,050,000 | 1.74% |
| Super Secrety Pty Limited <Tkocs Sf A/C> | 1,050,000 | 1.74% |
| Creight Investments Pty Ltd <Scutt Retirement Fund A/C> | 990,540 | 1.64% |
| Warwick Nettle Pty Limited <Warwick Nettle Superannuationfund A/C> | 967,040 | 1.60% |
| Phytose Corporatn Limited <Boundaryone S/F A/C> | 793,940 | 1.31% |
| Terrence Joseph Caplice | 730,440 | 1.21% |
| Citicorp Nominees Pty Limited | 687,913 | 1.14% |
| Dc Scutt Pty Ltd <Dcs Pension A/C> | 642,095 | 1.06% |
| Cinderella Management Company Pty Ltd <The Cinderella Unit A/C> | 608,694 | 1.01% |
| Rg Roden Pty Limited | 608,680 | 1.01% |
| Mr Paul Maxwell Bide | 600,000 | 0.99% |
| Bmy Group Pty Ltd | 543,478 | 0.90% |